It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Although three-dimensional (3D) bioprinting technology has gained much attention in the field of tissue engineering, there are still several significant engineering challenges to overcome, including lack of bioink with biocompatibility and printability. Here, we show a bioink created from silk fibroin (SF) for digital light processing (DLP) 3D bioprinting in tissue engineering applications. The SF-based bioink (Sil-MA) was produced by a methacrylation process using glycidyl methacrylate (GMA) during the fabrication of SF solution. The mechanical and rheological properties of Sil-MA hydrogel proved to be outstanding in experimental testing and can be modulated by varying the Sil-MA contents. This Sil-MA bioink allowed us to build highly complex organ structures, including the heart, vessel, brain, trachea and ear with excellent structural stability and reliable biocompatibility. Sil-MA bioink is well-suited for use in DLP printing process and could be applied to tissue and organ engineering depending on the specific biological requirements.
Although 3D bioprinting technology has gained much attention in the field of tissue engineering, there are still several significant challenges that need to be overcome. Here, the authors present silk fibroin bioink with printability and biocompatibility suited for digital light processing 3D printing.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Hallym University, Nano-Bio Regenerative Medical Institute, College of Medicine, Chuncheon, Republic of Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964)
2 George Washington University, School of Medicine, Washington, USA (GRID:grid.253615.6) (ISNI:0000 0004 1936 9510)
3 Kangwon National University, Division of Biomedical Convergence, College of Biomedical Science, Chuncheon, Republic of Korea (GRID:grid.412010.6) (ISNI:0000 0001 0707 9039)
4 Gachon University, Department of Molecular Medicine, School of Medicine, Incheon, Republic of Korea (GRID:grid.256155.0) (ISNI:0000 0004 0647 2973)
5 Chonbuk National University, Department of BIN Convergence Technology, Department of Polymer Nano Science & Technology and Polymer Materials Fusion Research Center, Jeonju, Republic of Korea (GRID:grid.411545.0) (ISNI:0000 0004 0470 4320)
6 Medical Center Boulevard, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, USA (GRID:grid.412860.9) (ISNI:0000 0004 0459 1231)
7 Hallym University, Nano-Bio Regenerative Medical Institute, College of Medicine, Chuncheon, Republic of Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964); Hallym University, Departments of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, School of Medicine, Chuncheon, Republic of Korea (GRID:grid.256753.0) (ISNI:0000 0004 0470 5964)